Oncology and Therapy最新文献

{"title":"Augmenting Performance Status: A Preliminary Study of Objective Kinematic Assessment Using Motion Capture.","authors":"Christopher Wang, Ajay Prasad, Elizabeth Qi, Jonathan Pai, Jade Law, Krithika Chennapan, Grant Jirka, Peter Kuhn, Mihir Tale, Luciano Nocera, Jorge Nieva","doi":"10.1007/s40487-026-00434-x","DOIUrl":"https://doi.org/10.1007/s40487-026-00434-x","url":null,"abstract":"<p><strong>Introduction: </strong>Understanding performance status (PS) is an essential aspect of oncologic care. PS is traditionally evaluated using the Karnofsky Performance Status (KPS) or Eastern Cooperative Oncology Group (ECOG) performance scales. Despite their ubiquity, these tools rely on subjective clinician interpretation and broad clinical categories, which contribute to poor inter-rater reliability and imprecise patient characterization. This study explores digital approaches to PS by leveraging three-dimensional video recordings and kinematic movement data to provide more objective, granular evaluations.</p><p><strong>Methods: </strong>In this single-center observational study, 34 oncology patients performed a standardized chair-to-table (CTT) movement. Of these participants, 52.9% were male and 47.1% were female. Patient movement was recorded using the Microsoft Kinect v2 sensor, which captures both color video (RGB) and depth-based skeletal tracking (Skeleton). Four oncologists independently reviewed the recordings and assigned KPS scores. Inter-rater reliability was assessed using the intraclass correlation coefficient (ICC). Pelvic acceleration metrics extracted from the Kinect data were correlated with summed KPS scores using Spearman's rank correlation.</p><p><strong>Results: </strong>The ICC for KPS scoring was 0.844 for RGB and 0.790 for Skeleton recordings, indicating good inter-rater reliability despite notable inter-observer variability. Vertical pelvic acceleration (mean and median) strongly correlated with summed KPS scores in both RGB (ρ ≈ 0.73-0.75, p < 0.0001) and Skeleton recordings (ρ ≈ 0.69-0.72, p < 0.0001). Horizontal and maximum acceleration showed weaker or nonsignificant associations.</p><p><strong>Conclusion: </strong>Kinect-derived motion capture offers an objective and reproducible approach to characterizing a patient's PS. Strong correlations between vertical pelvic acceleration and clinician-assigned KPS scores support its potential to augment both the accuracy and granularity of PS evaluation.</p><p><strong>Trial registry: </strong>ClinicalTrials.gov ID: NCT07082257.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147844210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.","authors":"Benoît Godbert, Elisa Gobbini, Yaacoub Khalife, Chantal Decroisette, Florence Brellier, Hervé Lena, Anne Fleuriet, Maeva Zysman, Thomas Egenod, Nicolas Girard","doi":"10.1007/s40487-026-00437-8","DOIUrl":"https://doi.org/10.1007/s40487-026-00437-8","url":null,"abstract":"<p><strong>Introduction: </strong>Nivolumab is approved for the treatment of advanced non-small cell lung cancer (aNSCLC) after prior chemotherapy. The Lung Initiative on Sequence Therapy (LIST) study evaluated long-term outcomes, safety and feasibility of immunotherapy rechallenge in French patients with previously treated aNSCLC in routine practice. We report the results of the final 24-month analysis.</p><p><strong>Methods: </strong>LIST was a longitudinal, prospective, observational study enrolling patients with aNSCLC who had received ≥ 1 prior line of therapy and were initiating treatment with nivolumab. Patients were classified into three cohorts according to prior immunotherapy exposure: immunotherapy-naïve (cohort 1); immunotherapy-experienced and discontinued prior immunotherapy for reasons other than immunotherapy-related toxicity (cohort 2); and discontinued because of immunotherapy-related toxicity (cohort 3). The primary endpoint was time to treatment discontinuation (TTD). Secondary endpoints included overall survival (OS), progression-free survival (PFS), response at 24 months, safety and quality of life (QoL).</p><p><strong>Results: </strong>A total of 522 patients were included (cohort 1, n = 280; cohort 2, n = 197; cohort 3, n = 45). Median TTD was 3.8, 3.2 and 3.4 months in cohorts 1, 2 and 3, respectively, with 24-month discontinuation-free rates of 7.9%, 6.0% and 7.1%. Median OS was 12.3, 9.5 and 9.8 months, and median PFS was 3.2, 2.6 and 3.9 months across cohorts 1, 2 and 3, respectively. Disease progression was the most common reason for nivolumab discontinuation. Numerically higher discontinuation-free rates were observed in patients who were younger (< 75 years), had better performance status, had non-squamous histology, were current smokers or had demonstrated prolonged benefit with prior immunotherapy. Safety outcomes were consistent with the established nivolumab profile, with no new safety signals. Among patients with available data, QoL changes were generally small.</p><p><strong>Conclusions: </strong>Consistent with results from previous analyses, this final 24-month analysis of LIST demonstrated real-world effectiveness and safety of nivolumab in patients with aNSCLC. Nivolumab rechallenge appears to be an option in selected patients, based on patient and disease characteristics and prior immunotherapy history.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier NCT04500535.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occupational Variation in the Incidence of Laryngeal Cancer in the Nordic Countries.","authors":"Timo Carpén, Zakarya Hadj-Allal, Rayan Nikkilä, Johnni Hansen, Sanna Heikkinen, Elsebeth Lynge, Jan Ivar Martinsen, Jenny Selander, Ingrid Sivesind Mehlum, Marcin W Wojewodzic, Jóhanna Eyrún Torfadottir, Antti Mäkitie, Eero Pukkala","doi":"10.1007/s40487-026-00436-9","DOIUrl":"https://doi.org/10.1007/s40487-026-00436-9","url":null,"abstract":"<p><strong>Introduction: </strong>Laryngeal cancer (LC) constitutes almost one third of the head and neck cancers, and its main risk factors, alcohol use and smoking, are well established. Our aim was to explore the variation in the incidence of LC between different occupations.</p><p><strong>Methods: </strong>This study was based on data from the Nordic Occupational Cancer Study (NOCCA), involving 14.9 million individuals from Denmark, Finland, Iceland, Norway, and Sweden. Occupational data from censuses were linked to cancer registry data from a period of up to 45 years (21,166 LC diagnoses) using personal identity codes. Standardized incidence ratios (SIRs) were calculated for different occupations, using the respective national populations as a reference.</p><p><strong>Results: </strong>Of the 21,166 patients with LC, 18,488 (87%) were men. The highest SIRs in men were noted among waiters (3.31, 95% confidence interval [CI] 2.69-4.02), beverage workers (2.51, 95% CI 1.91-3.24), and cooks and stewards (2.25, 95% CI 1.82-2.74). Among women, the highest SIRs were observed among building hands (7.37, 95% CI 3.53-13.55) and public safety workers (3.60, 95% CI 1.17-8.40). Farming and teaching occupations showed reduced SIRs in both sexes. The SIRs among male farmers, teachers, gardeners, and technical workers were reduced in all countries. The SIRs remained elevated and stable among cooks and stewards, waiters, packers, seamen, sales agents, and economically inactive males across the three 15-year periods from 1961 to 2005.</p><p><strong>Conclusion: </strong>The study confirms a major variation in the incidence of LC between occupations. The findings underscore the importance of considering lifestyle factors typical of each occupation in cancer risk assessments and the potential benefits of targeted prevention efforts.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.","authors":"Surbhi Sidana, Saurabh P Nagar, Sabyasachi Ghosh, Lin Fan, Victoria Alegria, Kevin C De Braganca, Tamar Lengil, Mukta Sharma, Helen Pai, Matthew Perciavalle, Jessica Maitland, Bruno Emond, Todd Bixby, Zaina P Qureshi, Rafael Fonseca","doi":"10.1007/s40487-026-00433-y","DOIUrl":"https://doi.org/10.1007/s40487-026-00433-y","url":null,"abstract":"<p><strong>Introduction: </strong>Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved in the USA for relapsed or refractory multiple myeloma (RRMM) as early as following first relapse, based on pivotal CARTITUDE-1 (≥ 4 prior lines of therapy [LOT]) and CARTITUDE-4 (1-3 prior LOT) trials, which reported high response rates and prolonged survival. In CARTITUDE-1 and CARTITUDE-4, rates of all-grade parkinsonism were 6% and < 1%, respectively, while rates of cranial nerve palsy were 3% and 9%, respectively. This study aimed to characterize new-onset nonimmune effector cell-associated neurotoxicity syndrome (non-ICANS) neurologic events (NEs) among patients with RRMM receiving cilta-cel after 1-3 or ≥ 4 prior LOT.</p><p><strong>Methods: </strong>This retrospective study used two real-world data sources: open and closed insurance claims from the Komodo Research Database (February 2021-November 2024), and electronic medical records from Loopback Analytics (February 2021-December 2024). New-onset non-ICANS NEs, including parkinsonism, cranial nerve palsy, and Guillain-Barré syndrome, were assessed from cilta-cel infusion until the end of clinical activity, death, or end of data availability. Analyses were conducted separately by database and stratified by LOT.</p><p><strong>Results: </strong>In patients with 1-3 prior LOT (Komodo: 124; Loopback: 79), over a median follow-up of 3.4-3.5 months, cranial nerve palsy occurred in 5.6% and 5.1% in Komodo and Loopback, respectively, with no parkinsonism or Guillain-Barré syndrome observed. In patients with ≥ 4 prior LOT (Komodo: 524; Loopback: 191), over a median follow-up of 13.2-13.3 months, parkinsonism occurred in 1.0% in both databases, cranial nerve palsy in 4.6% and 1.0%, and Guillain-Barré syndrome in 0.2% and 0.5% in Komodo and Loopback, respectively.</p><p><strong>Conclusions: </strong>In this real-world study, rates of non-ICANS NEs post-cilta-cel infusion across two databases were comparable to or lower than prior trials or real-world studies, reinforcing the favorable risk-benefit profile of cilta-cel in routine practice. Graphical Abstract available for this article.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147718573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telerehabilitation for Pain, Function, and Quality of Life in Patients with Cancer: A Systematic Review.","authors":"Leidy Tatiana Ordoñez-Mora, Diana Carolina Urrea-Arango, Juan Carlos Avila-Valencia, José Luis Estela-Zape, Marco Antonio Morales-Osorio, María Fernanda Serna-Orozco","doi":"10.1007/s40487-026-00431-0","DOIUrl":"https://doi.org/10.1007/s40487-026-00431-0","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer rehabilitation improves function, quality of life, and symptom control, yet access to specialized programs is limited by geographic, financial, and systemic barriers. Telerehabilitation has emerged as a scalable alternative; however, its effectiveness across cancer types and intervention modalities remains heterogeneous.</p><p><strong>Methods: </strong>We conducted a systematic review of randomized clinical trials (RCTs) and nonrandomized comparative studies evaluating telerehabilitation in adults with cancer. Searches were performed in MEDLINE, LILACS, ScienceDirect, PEDro, Cochrane Central, Scopus, Springer, Taylor & Francis, and Google Scholar from January 1, 2010 to September 30, 2025. Two reviewers independently screened studies and extracted data. Risk of bias was assessed using the PEDro scale (RCTs) and the MINORS tool (nonrandomized studies). Given heterogeneity in measures and outcome definitions, we applied structured narrative synthesis with vote counting (SWiM/Cochrane), complemented by effect-direction and albatross plots.</p><p><strong>Results: </strong>Thirteen studies (11 randomized controlled trials and 2 nonrandomized comparative trials) were included, encompassing populations with breast, lung, and esophageal cancers, hematologic malignancies, gliomas, and mixed cohorts. Interventions were categorized into three main delivery modalities: supervised synchronous exercise via videoconferencing, web- or app-based programs incorporating remote monitoring, and telephone-based counseling. Across studies, telerehabilitation consistently demonstrated improvements in physical function (e.g., walking capacity, muscular strength, and peak VO₂) and reductions in fatigue. Effects on pain were modest and heterogeneous, while outcomes related to health-related quality of life (HRQoL) were mixed. The most pronounced benefits were observed in supervised synchronous interventions, whereas asynchronous or maintenance models exhibited diminished effects, indicating a lower likelihood of achieving functional improvement. Adherence, as reported by the primary study authors, ranged from moderate to high, and no serious adverse events attributable to the interventions were documented.</p><p><strong>Conclusion: </strong>Telerehabilitation is a safe and effective strategy to improve function and reduce fatigue in oncology, with less consistent evidence for HRQoL and pain. Supervised synchronous models provide the strongest benefits. Multicenter RCTs with standardized outcomes and longer follow-up are needed.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts.","authors":"Désirée Deandreis, Heather Jacene, Patrick Therasse, Fabrice André, Fabrice Barlesi, Kevin Haigis, Karim Fizazi, Toni K Choueiri","doi":"10.1007/s40487-026-00432-z","DOIUrl":"https://doi.org/10.1007/s40487-026-00432-z","url":null,"abstract":"<p><p>Radiopharmaceutical therapy (RPT), the administration of a radioactive element coupled with a targeting vector, is one of the most promising innovations in oncology, supported by clinical trials. A theranostic approach-the pairing of diagnostic and therapeutic RPTs sharing the same target-facilitates selective delivery of therapeutic radiation to cancer cells. Its advantages and limitations are determined by the molecular targeting mechanisms employed, as well as the types of ionising radiation emitted. Therefore, understanding the biology of cell-surface targets and molecular mechanisms governing target expression in cancers is critical to the development and clinical use of these agents. This review provides an overview of the latest advances in the application of targeted RPTs within oncology, as discussed at the Fourth Transatlantic Exchange in Oncology, a hybrid conference held in March 2025 that brought together experts from Dana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Paris, France). Key topics included the targeting of prostate-specific membrane antigen (PSMA) for both imaging and therapy purposes in prostate cancer. In particular, PSMA-based imaging-encompassing both positron emission tomography (PET) and single-photon emission computed tomography (SPECT)-has become a fundamental tool for patient selection, evaluation of treatment response, and personalisation of therapeutic strategies. While theranostic approaches continue to pose challenges, they should increasingly enable improved treatment selection for patients with cancer, and more effective prediction of response and toxicity. Lessons learned from PSMA may apply to other emerging theranostic targets in prostate cancer and other tumour types, expanding the future potential of RPT applications. Beyond current achievements, new molecules and intensive translational research programs may optimise, potentiate and direct RPT. The impact of the expanding use of RPTs on healthcare systems was also addressed, defining strategies to overcome barriers and provide broader access to innovations in RPT in both clinical and research settings.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor^® (Mechlorethamine) in the Treatment of CTCL.","authors":"Brian Poligone, Christopher Pullion, Adam Rumage, Richard Straube, Oreola Donini, Christopher J Schaber, Elaine S Gilmore","doi":"10.1007/s40487-026-00430-1","DOIUrl":"https://doi.org/10.1007/s40487-026-00430-1","url":null,"abstract":"<p><strong>Introduction: </strong>Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL), a malignant and chronic skin disease. Early-stage MF has a generally favorable prognosis, but effective and well-tolerated skin-directed therapies are crucial for management. HyBryte™ is a photodynamic therapy of topical hypericin that was recently shown to be well tolerated and efficacious in early-stage CTCL. Valchlor^® (mechlorethamine) is an approved second-line therapy for use in early-stage CTCL after other topical therapies. This study compared Valchlor^® to HyBryte™ following 12 weeks of treatment. The objectives in this study were (i) to obtain preliminary comparative assessment of safety and efficacy of Valchlor^® versus HyBryte™ through 12 weeks of treatment, and (ii) to better understand the impact of HyBryte™ application on the measurement of modified Composite Assessment of Index Lesion Severity (mCAILS).</p><p><strong>Methods: </strong>This was an open-label trial enrolling 10 patients with CTCL (stage IA, IB, or IIA) randomized 1:1 to receive topical HyBryte™ or topical Valchlor^® for 12 weeks.</p><p><strong>Results: </strong>The overall response rate (ORR, i.e., complete responders + partial responders) was 60% (3/5) in the HyBryte™ treatment group and 20% (1/5; not significant) in the Valchlor^® treatment group over 12 weeks. HyBryte™ demonstrated no local adverse events at application sites, while 60% (3/5) of patients treated with Valchlor^® had skin reactions, including one case which led to study withdrawal.</p><p><strong>Conclusions: </strong>This is a single-center, open-label study. It is a pilot study requiring additional research to confirm its results. This study demonstrated the favorable safety and efficacy profile of HyBryte™ compared to Valchlor^® in patients with CTCL. HyBryte™ showed higher treatment success rates and was better tolerated.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT06149247; registered November 20, 2023.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study.","authors":"Binod Dhakal, Moshe Y Levy, Gilbert Ko, Jinghua He, Nina Kim, Wenze Tang, Tonya Le Blanc, Jessica Fowler, Sarah Lucht, Madison Brown, Emily Bland, Camryn Craig, Sarah Giegerich, JaLyna Laney, Bruce Feinberg, Niodita Gupta-Werner, Shuchita Kaila, Peter Voorhees","doi":"10.1007/s40487-026-00429-8","DOIUrl":"https://doi.org/10.1007/s40487-026-00429-8","url":null,"abstract":"<p><strong>Introduction: </strong>Teclistamab is an established standard of care for the treatment of relapsed/refractory multiple myeloma (RRMM) based on MajesTEC-1 study results. United States (US)-based real-world studies of teclistamab treatment have had limited follow-up, were conducted in academic settings and/or had small sample sizes. This real-world study was conducted in a primarily US community-based oncology provider network to assess the real-world effectiveness and safety profile of teclistamab.</p><p><strong>Methods: </strong>This retrospective, observational, cohort study used Cardinal Health's Oncology Provider Extended Network. Adult patients with RRMM who received teclistamab on or after 25 October 2022, were identified through medical chart review. Patient characteristics, treatment patterns, and treatment history were described. Clinical outcomes included adverse events, response and survival rates, and duration of response. Data are presented for all patients and US Prescribing Information (USPI)-aligned and unaligned subgroups.</p><p><strong>Results: </strong>The overall population included 101 patients, of which 30 and 71 were USPI-aligned and USPI-unaligned, respectively. Median age was 65.4 years, 86.1% had an Eastern Cooperative Oncology Group Performance Status score of 1 and 37.6% had a high-risk cytogenetic profile. Most patients were triple-class exposed (93.1%) and/or refractory (65.3%). Median follow-up was 13.8 months and overall response rates were 80.2%, 90.0%, and 76.1% in the overall, USPI-aligned, and USPI-unaligned subgroups, respectively. During step-up dosing, 32.7% and 8.9% of all patients had cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, respectively; 26.7% of all patients developed infections while receiving teclistamab.</p><p><strong>Conclusion: </strong>This real-world study demonstrated numerically higher response rates and broadly similar rates of adverse events in this population compared with the MajesTEC-1 trial, despite many patients having higher disease burden and worse performance status. These findings from primarily community oncology settings suggest that teclistamab is an effective treatment option for patients with RRMM in the real world.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature Review.","authors":"Meral Beksac, Mohamed Samra, Omar Abduljalil, Hasan Aal Yaseen, Sevgi Besisik, Guldane Cengi̇z Seval, Ashraf Elghandour, Gamal Fathy, Güner Hayri Özsan, Mahmoud Marashi, Ömür Gökmen Sevindik, Ruba Yaseen Ibrahim Taha, Bhumika Aggarwal, Jorge Mouro, Abhay Phansalkar","doi":"10.1007/s40487-026-00428-9","DOIUrl":"https://doi.org/10.1007/s40487-026-00428-9","url":null,"abstract":"<p><p>Globally, the multiple myeloma (MM) landscape varies widely, with incidence, treatment patterns, outcomes, and healthcare resource utilization (HCRU) differing across countries and regions. Many factors contribute to these differences, including ethnicity, awareness, and socioeconomic influences. This is the first analysis aiming to explore factors associated with myeloma incidence and patient characteristics in the Middle East and North Africa (MENA) region. A literature search was conducted using PubMed and Embase from 1 January 2015 to 30 May 2025. Articles reporting outcomes of interest in patients with MM in the relevant MENA countries (Egypt, Saudi Arabia, Turkey, and the United Arab Emirates) were identified. Of 1400 articles identified in the search, 94 were included; four articles were added post hoc as gray literature. Most reported findings from retrospective observational studies (n = 66); more than half were conducted in Turkey. The age-standardized incidence rate in MENA was 1.49 per 100,000 people in 2019; median age at diagnosis was lower in the region (range 43-70 years) than that in global reports (70 years). Nearly half (49.7%) of all patients were treated with a regimen containing bortezomib; the second-most frequently used drug was lenalidomide in newly diagnosed MM and daratumumab in relapsed/refractory MM. Few patients (< 1%) were treated with quadruplet regimens. Overall response rates were generally high (35-90.2%), while survival outcomes varied (median progression-free and overall survival ranged from 2-97.7 months and 4-125.3 months, respectively). Adverse events were inconsistently reported across the studies; hematologic adverse events and peripheral neuropathy were commonly reported. HCRU data in the region were limited. We identified a paucity of comprehensive data on the epidemiology and management of MM in MENA. Improved understanding of treatment patterns and HCRU in the region may provide pathways to advancing access to newer therapies that can alleviate the disease and treatment burden of MM in MENA.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO).","authors":"Cristina Papayannidis, Irina Amitai, Pascal Turlure, Ann De Becker, Felix Mensah, Dina Elsouda, Ioanna Vardounioti, Jose Alejandro Palacios-Fabrega, Paresh Vyas, Blanca Boluda","doi":"10.1007/s40487-026-00427-w","DOIUrl":"https://doi.org/10.1007/s40487-026-00427-w","url":null,"abstract":"<p><strong>Introduction: </strong>FMS-like tyrosine kinase 3 (FLT3) mutations show variable detectability in relapse/refractory acute myeloid leukemia (AML) with unclear clonal evolution dynamics.</p><p><strong>Methods: </strong>This prospective noninterventional study examined clonal evolution and outcomes from AML diagnosis to relapse/refractory disease occurrences.</p><p><strong>Results: </strong>Of 650 patients included, 172 were FLT3-positive (FLT3^pos) and 472 were FLT3-negative (FLT3^neg; 99.1% testing rate; unknown FLT3 status, six patients). At first occurrence, the FLT3 testing rate decreased (57.0% [166/291]). Among tested patients, 45 had FLT3^pos and 121 had FLT3^neg AML. A gain or loss of mutations was seen in 15.6% (7/45) of patients with FLT3^pos AML and 14.9% (18/121) of patients with FLT3^neg AML. Median (95% confidence interval [CI]) overall survival was 22.8 (19.6, not estimable [NE]) months across patients (FLT3^pos, NE;FLT3^neg, 20.3 [15.2-23.7] months; hazard ratio [HR] [95% CI] 0.6 [0.5-0.8]). Median (95% CI) disease-free survival across patients was NE (26.3-NE) (FLT3^pos, NE;FLT3^neg, NE; HR [95% CI] 0.8 [0.6-1.1]). Median event-free survival (95% CI) was 11.8 (10.0-15.5) months in all patients (FLT3^pos, 17.2 [11.0-NE] months;FLT3^neg, 10.4 [8.4-13.2] months; HR [95% CI] 0.8 [0.6-1.0]).</p><p><strong>Conclusions: </strong>Dynamic changes in FLT3 mutation status were observed during these patients' disease course. FLT3^pos status at baseline, but not at first occurrence, was associated with improved outcomes; other confounders should be considered. Timelier FLT3 mutation retesting may aid in personalizing treatment. Graphical abstract available for this article.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}